Zim Laboratories Ltd

- The transcript does not provide explicit figures or detailed quantification of the current or expected order book or pending orders for ZIM Laboratories Limited. - Management mentions supply agreements with partners who have obtained marketing authorizations using their dossiers, signaling some order flow from these arrangements. - Approvals have been received for products like Sildenafil and Rizatriptan, with revenue expected to start by Q2 or Q3 of the relevant fiscal year. - Future growth is anticipated from regulated markets such as Europe and South America, but no specific order book size is shared. - There is an indication of dossier filing income bundled under other income but difficult to quantify currently; more elaborate disclosures might come in future quarters as the business grows. - Overall, order information is still evolving alongside approvals and partner agreements, typical of a pharmaceutical company in a transformative growth stage.

- No specific mention of any immediate new fundraising through debt or equity in the current period. - Management indicated that debt levels have been reduced and are expected to remain stable unless major CapEx demands arise. - Bank sanctions and debt facilities are already in place should future CapEx require additional borrowing. - No plans for large new equity fundraising were disclosed at this time. - Company aims to manage growth and CapEx needs judiciously and conservatively within existing financial arrangements. - Further clarity on debt and fundraising expected to be shared by next quarter as more details become available.

- Most of the recent CapEx was towards warehouse development (~INR 117 million) and capacity balancing, including packing material and packing belt capacity enhancements. - Ongoing capitalization will continue into next year. - Expansion plans include automation of existing packaging lines to increase efficiency. - There is expansion ongoing in the existing campus with new blocks dedicated to NIP (Novel Innovative Products) anticipating higher volumes. - Plans for nutraceutical facility expansion include a new greenfield plant. - Existing facilities are currently operating at around 60% utilization, considered optimal. - Future CapEx is expected to be on a similar line as current, focusing on capacity enhancements without the need for new separate large facilities. - Bank sanctions for debt are in place to support CapEx if needed. - Brownfield expansions expected with no additional large land purchases planned.

Future growth expectations for ZIM Laboratories Limited are as follows: - Expect an increase in regulated market sales contribution from current ~6%-7% to between 15%-20% over the next few years, mainly from Europe and South America. - Growth driven by innovative NIP (New Innovative Products) and Oral Thin Film (OTF) products, with approvals expected within 18-24 months. - Revenue growth anticipated to accelerate from historical 8%-10% to upper teens or even 15%-20%, mainly from new filings and products entering regulated markets. - Out-licensing and dossier income expected to contribute increasingly to revenue starting as early as Q2/Q3 FY24. - Existing business in Rest of World (RoW) and MENA markets expected to grow steadily at upper teens. - EBITDA margins expected to improve due to higher value innovative products. - Infrastructure expansions and capacity upgradation planned to support growth without requiring large new CapEx facilities.

- The company expects future growth primarily from Novel Innovative Products (NIP) in regulated markets, with revenues likely starting from late 2024 or early 2025. - Existing business in Rest of World (RoW) and MENA regions is projected to grow at upper teens percentage annually. - EBITDA and operating margins are expected to improve over time, with new products having higher margins than the current 12%-13% operating level. - Management anticipates doubling the share of regulated market revenue to 15%-20% of total mix in the coming years. - Cost of debt has been reduced to about 10.5%, supporting improved profitability. - Expansion includes capacity enhancement projects and a new greenfield nutraceutical plant to support growth. - Earnings growth and margin expansion reflect the move up the value chain with more complex, high-value products and markets.